Background Rituximab, an anti-CD20 monoclonal antibody that depletes CD20+ B cells, has
demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be …

Purpose Rituximab is widely prescribed to treat systemic sclerosis (SSc) by the depletion of
pathogenic B cells. Nonetheless, the clinical benefit of Rituximab in SSc remains …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …

Objectives: To assess the efficacy and safety of rituximab for multiple sclerosis (MS)
treatment in terms of reduction in clinical relapses, magnetic resonance imaging (MRI) …

Objective To describe 2 patients with relapsing-remitting multiple sclerosis (RRMS)
receiving long-term treatment with the monoclonal antibody rituximab. The clinical and …

Background Despite positive results from phase II and observational studies, Rituximab
(RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used …

In the last decades, evidence suggesting the direct or indirect involvement of B cells on
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …

Objective To investigate the association between demographic characteristics, disease
characteristics, the number of rituximab (RTX) rounds, and concurrent immunosuppression …

It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal
antibody that selectively depleted B cells, was approved by the FDA for the treatment of …

Background Rituximab is extensively used for multiple sclerosis (MS) treatment. However,
the best dosage remains to be established. It has been proposed that retreatment could be …